Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Nicolas Folschweiller, Ulrich Behre, Marc Dionne, Paolo Durando, Susanna Esposito, Linda Ferguson, Murdo Ferguson, Peter Hillemanns, Shelly A. McNeil, Klaus Peters, Brian Ramjattan, Tino F. Schwarz, Khuanchai Supparatpinyo, Pemmaraju V. Suryakirian, Michel Janssens, Philippe Moris, Annabelle Decreux, Sylviane Poncelet, Frank Struyf

Research output: Contribution to journalArticle

Abstract

This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following 3 doses in women aged 15-25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4+ T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.

Original languageEnglish
Pages (from-to)1799-1803
Number of pages5
JournalThe Journal of infectious diseases
Volume219
Issue number11
DOIs
Publication statusPublished - May 5 2019

Keywords

  • AS04-HPV-16/18 vaccine
  • cross-reactivity
  • HPV-31
  • HPV-45
  • immunogenicity
  • nonvaccine types

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine'. Together they form a unique fingerprint.

  • Cite this

    Folschweiller, N., Behre, U., Dionne, M., Durando, P., Esposito, S., Ferguson, L., Ferguson, M., Hillemanns, P., McNeil, S. A., Peters, K., Ramjattan, B., Schwarz, T. F., Supparatpinyo, K., Suryakirian, P. V., Janssens, M., Moris, P., Decreux, A., Poncelet, S., & Struyf, F. (2019). Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine. The Journal of infectious diseases, 219(11), 1799-1803. https://doi.org/10.1093/infdis/jiy743